DDD Partners LLC has significantly increased its investment in **Danaher Corporation** (NYSE: DHR), boosting its stake by an astonishing **7,732.8%** during the third quarter of 2023. According to **HoldingsChannel.com**, the institutional investor now holds **92,270 shares** of Danaher following the acquisition of an additional **91,092 shares** during this period. As of its latest filing with the **Securities and Exchange Commission (SEC)**, DDD Partners LLC’s holdings in Danaher are valued at approximately **$18.3 million**.
This investment represents **1.2%** of DDD Partners LLC’s total portfolio, making Danaher its **27th largest holding**. The surge in investment comes at a time when several other institutional investors and hedge funds are also acquiring shares in Danaher. For instance, **WFA of San Diego LLC** entered a new position in the company during the second quarter, valued at **$26,000**, while **Howard Hughes Medical Institute** acquired shares worth **$27,000**.
Additionally, **TruNorth Capital Management LLC** purchased a stake in Danaher valued at around **$28,000** during the third quarter, and **Tripletail Wealth Management LLC** made an investment worth roughly **$31,000**. Lastly, **Heartwood Wealth Advisors LLC** entered the market with a position valued at about **$37,000**. Notably, institutional investors collectively own **79.05%** of Danaher’s stock.
Analyst Ratings and Stock Performance
Several research firms have recently provided updates on Danaher’s stock. **Evercore** reissued an “outperform” rating with a price target of **$254.00** on **January 28, 2024**. Similarly, **Deutsche Bank Aktiengesellschaft** maintained a “buy” rating, while **Robert W. Baird** set a target price of **$251.00**. On average, **twenty analysts** have rated Danaher with a buy rating, with an average price target of **$253.86**, according to data from **MarketBeat.com**.
As of **January 26, 2024**, shares of Danaher opened at **$212.37**. The stock has experienced fluctuations over the past year, reaching a low of **$171.00** and a high of **$242.80**. The company’s market capitalization stands at **$150.01 billion**, with a price-to-earnings (P/E) ratio of **42.14**. Danaher’s 50-day simple moving average is **$228.63**, while the 200-day moving average is **$215.46**.
The company last reported its earnings on **January 27, 2024**, revealing earnings per share (EPS) of **$2.23**, surpassing the consensus estimate of **$2.14** by **$0.09**. Danaher’s revenue for the quarter reached **$6.84 billion**, exceeding expectations of **$6.79 billion**. This marks a **4.6%** year-over-year increase in revenue.
Dividend and Insider Activity
Danaher also recently announced a quarterly dividend of **$0.32**, which was paid on **January 30, 2024**. Investors who were recorded as shareholders on **December 26, 2023**, received this dividend, resulting in an annualized yield of **0.6%**. The company’s dividend payout ratio currently stands at **25.40%**.
In related news, **Teri List**, a director at Danaher, sold **3,298 shares** on **November 18, 2023**, at an average price of **$226.50**, totaling approximately **$746,997**. Post-sale, List holds **20,762 shares** valued at around **$4.7 million**, reflecting a **13.71%** decrease in her position. The transaction details were disclosed in a filing with the SEC.
Danaher Corporation operates as a global science and technology entity, focusing on products and services across life sciences, diagnostics, and environmental markets. Its diverse portfolio includes analytical instruments, laboratory consumables, digital solutions, and various services catering to research and clinical testing, among others.
For those interested in tracking hedge fund activities related to Danaher, **HoldingsChannel.com** provides regular updates on 13F filings and insider trading related to the company.
